- Adjuvant VEGF Inhibitors, Sorafenib or Sunitinib, do not Improve Outcomes in Resected Locally-Advanced Renal Carcinoma
- FDA Approves Panobinostat for Treatment of Multiple Myeloma
- FDA Permits Marketing of First Direct-to-Consumer Genetic Carrier Test for Bloom Syndrome
- Genomic Profiling of Cancer of Unknown Primary Site
- FDA Approves Lenvatinib for Differentiated Thyroid Cancer Refractory to Iodine-131
- Estimates of Gastric, Breast Cancer Risk in CDH1 Gene Mutation Carriers
Providing practical opinion to support best practice for busy healthcare professionals